89bio Inc ETNB

Overview

89bio, Inc. is a clinical-stage biopharmaceutical company that is at the forefront of developing innovative therapies designed to combat liver and cardio-metabolic diseases. The company, which was founded in 2018, reflects a modern approach to addressing these serious health issues, leveraging cutting-edge science and medical research. Based in San Francisco, California, 89bio is dedicated to transforming the treatment landscape for patients suffering from these conditions, with a focus on nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia, among others.

Products and Services

• Pegozafermin

Pegozafermin stands out as 89bio's leading product candidate, embodying the company's commitment to innovation in treating liver and cardio-metabolic diseases. It is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), which offers a novel approach to managing conditions characterized by metabolic dysfunction. Pegozafermin is currently under clinical development for two primary applications:

• Treatment of Nonalcoholic Steatohepatitis (NASH): A serious liver disease characterized by fat accumulation, inflammation, and damage, NASH is a leading cause of cirrhosis and liver failure. Pegozafermin aims to address the underlying metabolic disturbances contributing to NASH, offering hope for patients with this condition.
• Treatment of Severe Hypertriglyceridemia: This condition is marked by extremely high levels of triglycerides in the blood, increasing the risk of cardiovascular disease. By leveraging the metabolic-regulating properties of FGF21, pegozafermin offers a promising approach to reducing triglyceride levels and thereby mitigating the risk of associated heart conditions.